Ivabradine is expected to have a 95% chance of being cost-effective in the EU licensed population using the current National Institute for Health and Care Excellence cost effectiveness threshold of £20 000 per QALY.
The WWR cost effectiveness and ease in construction could accelerate the application of non-proprietary UHPC and WWR in bridge construction.
In return, it increases Competitiveness, Cost effectiveness, Profitability, Higher market share, Brand image, Revenues and Growth, Customer perception, Product/service performance, Credibility and Innovation success rate.
Additionally, the NICE cost effectiveness analysis assumed a much lower prevalence of LTBI in contacts (8%).
A recent empirical estimate to update the HD cost effectiveness standard arrived at an average of $129,000 per Quality Added Life Years (QALY) with a wide distribution.
We consider the simplicity of these assumptions justified as a first attempt to include a replenishment programme into a model of ITN cost effectiveness.
Although both these outcomes were not statistically significant, it would be important to consider them in future studies evaluating TXA cost effectiveness.
The NAGS cost effectiveness analysis was based upon improvement in adherence between the two groups and as such the data were dominated by the control treatment.
In order to determine whether ivabradine represented value for money, the incremental cost effectiveness ratio (ICER) was compared with the NICE cost effectiveness threshold range of £20 000 to £30 000 per QALY.
The results from both studies show that treating all patients irrespective of fibrosis level is cost-effective at UK cost-effectiveness thresholds.
The ICER of Strategy 8 versus Strategy 7 was £82,962/QALY, substantially greater than the UK cost-effectiveness threshold of £20,000 per QALY, suggesting that direct reflex mutation testing is not cost-effective in early-onset CRC patients.
